Imaging brain tumors using a targeted radioimmunoconjugate and PET scans

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase I trial evaluates the effectiveness of zirconium (Zr)-89 crefmirlimab berdoxam in identifying immune cell activity in patients with resectable brain tumors. The study aims to verify the specificity of this radioimmunoconjugate in detecting CD8+ tumor infiltrating lymphocytes through immuno-positron emission tomography (PET) imaging. Patients will receive the Zr-89 crefmirlimab berdoxam intravenously before undergoing PET scans and standard surgical tumor resection. The trial also explores correlations between imaging results, immune responses, and clinical outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female \>= 18 years of age
* Documentation of a diagnosis of brain tumor including brain metastases, any grade of gliomas and meningiomas
* The participant is scheduled for standard of care surgical tumor resection
* The participant (or legally acceptable representative if applicable) provides written informed consent for the trial

Exclusion Criteria:

* Male or female \< 18 years of age
* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data
* Not medically cleared for surgery
* Individuals who cannot tolerate MRI scan or PET/CT scan
* Pregnant or breast-feeding women
* Serum creatinine OR measured or calculated creatinine clearance (Glomerular filtration rate \[GFR\] can be use in place of creatinine or creatinine clearance \[CrCl\]) =\< 1.5 X institutional upper limit of normal (ULN) OR \>= 60mL/min for subjects with creatinine levels \> 1.5 X institutional ULN

  * Creatinine clearance should be calculated per institutional standard
* Serum total bilirubin: =\< 1.5 X institutional ULN OR direct bilirubin =\< institutional ULN for subjects with total bilirubin levels \> 1.5 institutional ULN
* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \[SGPT\]) =\< 2.5 X institutional ULN OR =\< 5 X institutional ULN for subjects with Gilberts syndrome
* Albumin \>= 2.5 mg/dL
* Patients with splenic dysfunction or post splenectomy
* Any abnormalities that would be a contraindication to gadolinium-based contrast agent

Where it's running

• UCLA / Jonsson Comprehensive Cancer Center
  Los Angeles, California, United States Recruiting

Study contacts

• Principal investigator: Robert M Prins — UCLA / Jonsson Comprehensive Cancer Center
• Study coordinator: Sichen Li
• Email: sichenli@mednet.ucla.edu
• Phone: 310-592-9091

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Skin closure after brain tumor surgery: running absorbable versus interrupted non-absorbable sutures

  This will test whether absorbable running intradermal sutures or non-absorbable interrupted transdermal sutures produce better wound healing after craniotomy in adults with supratentorial brain tumors.

  Recruiting Medical University of Warsaw · Warsaw, Masovian Voivodeship · NCT07413796

• Cerebrospinal fluid leak after brain tumor surgery

  This project will look at adults having planned supratentorial craniotomy for intracranial tumors to see how often cerebrospinal fluid leaks occur and what complications they cause.

  Recruiting Medical University of Warsaw · Warsaw · NCT07411690

• Advanced MRI to distinguish recurrent brain tumor from radiation necrosis

  This trial tests whether advanced MRI scans (DR-CSI and sodium imaging) can tell if people with metastatic brain tumors have tumor recurrence or treatment-related radiation necrosis.

  Recruiting Jonsson Comprehensive Cancer Center · Los Angeles, California · NCT07339085

• Pharmacoscopy-guided treatment for refractory brain tumors

  This trial tests whether personalized drug testing on a patient’s tumor cells can guide treatment choices for adults with hard-to-treat brain cancers like glioblastoma.

  Recruiting Phase 2 University of Zurich · Basel, Basel-Landschaft and 2 other locations · NCT06804655

• Combining TIL Therapy and Pembrolizumab for Advanced Brain Cancer

  This study is testing a new treatment that combines a type of immune therapy using patients' own tumor cells with Pembrolizumab to see if it helps people with advanced brain cancer feel better and live longer.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT06640582

• Dexamethasone dosing after brain tumor surgery

  This study is testing if a lower dose of dexamethasone after brain tumor surgery can help reduce side effects for patients compared to the usual dose.

  Recruiting Phase 2 Emory University · Atlanta, Georgia · NCT06132685

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.